{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:35:10Z","timestamp":1783103710874,"version":"3.54.6"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jns.2017.01.061","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T07:35:04Z","timestamp":1485329704000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Immunoglobulin therapy in the treatment of multifocal motor neuropathy"],"prefix":"10.1016","volume":"375","author":[{"given":"Aditya","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huned S.","family":"Patwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.jns.2017.01.061_bb0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0165-5728(01)00266-1","article-title":"Multifocal motor neuropathy","volume":"115","author":"Nobile-Orazio","year":"2001","journal-title":"J. Neuroimmunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2017.01.061_bb0010","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1007\/s10875-012-9779-8","article-title":"Immune pathogenesis and treatment of multifocal motor neuropathy","volume":"33","author":"Vlam","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0960-8966(00)00191-7","article-title":"79(th) ENMC international workshop: multifocal motor neuropathy. 14\u201315 April 2000, Hilversum, The Netherlands","volume":"11","author":"Hughes","year":"2001","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"10.1016\/j.jns.2017.01.061_bb0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<900::AID-MUS9>3.0.CO;2-Y","article-title":"Natural history of 46 patients with multifocal motor neuropathy with conduction block","volume":"23","author":"Taylor","year":"2000","journal-title":"Muscle Nerve"},{"issue":"17","key":"10.1016\/j.jns.2017.01.061_bb0025","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/01.wnl.0000277697.55288.d0","article-title":"Multifocal motor neuropathy: the diagnostic spectrum and response to treatment","volume":"69","author":"Slee","year":"2007","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2017.01.061_bb0030","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1212\/WNL.0b013e3181f0738e","article-title":"Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy","volume":"75","author":"Cats","year":"2010","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2017.01.061_bb0035","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.36.9.1260","article-title":"Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome","volume":"36","author":"Chad","year":"1986","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2017.01.061_bb0040","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000116045","article-title":"Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia","volume":"25","author":"Roth","year":"1986","journal-title":"Eur. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2017.01.061_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mus.880110203","article-title":"Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease","volume":"11","author":"Parry","year":"1988","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2017.01.061_bb0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2017.01.061_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnen\/63.2.129","article-title":"Multifocal motor neuropathy: pathologic alterations at the site of conduction block","volume":"63","author":"Taylor","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"22","key":"10.1016\/j.jns.2017.01.061_bb0060","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1212\/WNL.0b013e3181ff94c2","article-title":"Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features","volume":"75","author":"Cats","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0065","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ana.410270314","article-title":"Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies","volume":"27","author":"Pestronk","year":"1990","journal-title":"Ann. Neurol."},{"issue":"Pt 12","key":"10.1016\/j.jns.2017.01.061_bb0070","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and anti-glycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.jns.2017.01.061_bb0075","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/glia.20503","article-title":"Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers","volume":"55","author":"Susuki","year":"2007","journal-title":"Glia"},{"issue":"15","key":"10.1016\/j.jns.2017.01.061_bb0080","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","article-title":"Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers","volume":"27","author":"Susuki","year":"2007","journal-title":"J. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.01.061_bb0085","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jneuroim.2010.08.023","article-title":"IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN","volume":"229","author":"Piepers","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.jns.2017.01.061_bb0090","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.expneurol.2011.11.039","article-title":"Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies","volume":"233","author":"Susuki","year":"2012","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2017.01.061_bb0095","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.mcn.2010.07.008","article-title":"Anti-GM1 antibodies affect the integrity of lipid rafts","volume":"45","author":"Ueda","year":"2010","journal-title":"Mol. Cell. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2017.01.061_bb0100","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1007\/s10875-014-0026-3","article-title":"MMN: from immunological cross-talk to conduction block","volume":"34","author":"Harschnitz","year":"2014","journal-title":"J. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jns.2017.01.061_bb0105","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/1531-8249(200012)48:6<919::AID-ANA13>3.0.CO;2-J","article-title":"Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment","volume":"48","author":"Van den Berg-Vos","year":"2000","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.01.061_bb0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mus.10317","article-title":"American Association of Electrodiagnostic M. Consensus criteria for the diagnosis of multifocal motor neuropathy","volume":"27","author":"Olney","year":"2003","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0115","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11940-013-0229-6","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"15","author":"Dimachkie","year":"2013","journal-title":"Curr. Treat. Options Neurol."},{"issue":"21","key":"10.1016\/j.jns.2017.01.061_bb0120","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study","volume":"74","author":"Ruts","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2017.01.061_bb0125","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1212\/01.wnl.0000234063.51897.20","article-title":"Multifocal motor neuropathy with and without conduction block: a single entity?","volume":"67","author":"Delmont","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2017.01.061_bb0130","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"European Federation of Neurological S. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2017.01.061_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004429.pub2","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"2","author":"van Schaik","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3 Pt 1","key":"10.1016\/j.jns.2017.01.061_bb0140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","article-title":"Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study","volume":"44","author":"Azulay","year":"1994","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2017.01.061_bb0145","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1212\/WNL.45.5.987","article-title":"Improvement of multifocal motor neuropathy during long-term weekly treatment with human immunoglobulin","volume":"45","author":"Van den Berg","year":"1995","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","article-title":"Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study","volume":"59","author":"Van den Berg","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.jns.2017.01.061_bb0155","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","article-title":"Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study","volume":"55","author":"Federico","year":"2000","journal-title":"Neurology"},{"issue":"Pt 1","key":"10.1016\/j.jns.2017.01.061_bb0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study","volume":"124","author":"Leger","year":"2001","journal-title":"Brain"},{"issue":"8232","key":"10.1016\/j.jns.2017.01.061_bb0165","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jns.2017.01.061_bb0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jns.2017.01.061_bb0175","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immune globulin therapy for neurologic diseases","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.jns.2017.01.061_bb0180","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1567-5769(03)00134-6","article-title":"Comparison of the efficacy of IGIV-C, 10% (caprylate\/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial","volume":"3","author":"Roifman","year":"2003","journal-title":"Int. Immunopharmacol."},{"issue":"8794","key":"10.1016\/j.jns.2017.01.061_bb0185","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0140-6736(92)90806-E","article-title":"Effect of high-dose intravenous immunoglobulin therapy on blood rheology","volume":"339","author":"Reinhart","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2017.01.061_bb0190","first-page":"1","article-title":"Metabolism of immunoglobulins","volume":"13","author":"Waldmann","year":"1969","journal-title":"Prog. Allergy"},{"issue":"3A","key":"10.1016\/j.jns.2017.01.061_bb0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0002-9343(84)90320-6","article-title":"Intravenous immune globulin therapy in hypogammaglobulinemia. A review","volume":"76","author":"Pirofsky","year":"1984","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2017.01.061_bb0200","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"13","key":"10.1016\/j.jns.2017.01.061_bb0205","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.01.061_bb0210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/B978-0-444-63432-0.00027-X","article-title":"Current and future immunotherapy targets in autoimmune neurology","volume":"133","author":"Hu","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2017.01.061_bb0215","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/jnnp-2013-306227","article-title":"Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy","volume":"85","author":"Vlam","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2017.01.061_bb0220","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2249.2008.03620.x","article-title":"Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies","volume":"152","author":"Gustafson","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"5503","key":"10.1016\/j.jns.2017.01.061_bb0225","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jns.2017.01.061_bb0230","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.56.6.661","article-title":"Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases","volume":"56","author":"Stangel","year":"1999","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2017.01.061_bb0235","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood.V93.11.3624","article-title":"Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg)","volume":"93","author":"Vassilev","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jns.2017.01.061_bb0240","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.01.061_bb0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug insight: the use of intravenous immunoglobulin in neurology\u2014therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.01.061_bb0250","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410390121","article-title":"Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen","volume":"39","author":"Malik","year":"1996","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.01.061_bb0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0022-510X(96)00053-6","article-title":"Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies","volume":"139","author":"Yuki","year":"1996","journal-title":"J. Neurol. Sci."},{"issue":"Pt 5","key":"10.1016\/j.jns.2017.01.061_bb0260","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awh127","article-title":"Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies","volume":"127","author":"Zhang","year":"2004","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jns.2017.01.061_bb0265","first-page":"349","article-title":"Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)","volume":"152","author":"Lacroix-Desmazes","year":"1996","journal-title":"Rev. Neurol. (Paris)"},{"issue":"1","key":"10.1016\/j.jns.2017.01.061_bb0270","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/jnnp.2010.205856","article-title":"IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy","volume":"82","author":"Yuki","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2017.01.061_bb0275","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2\u20133","key":"10.1016\/j.jns.2017.01.061_bb0280","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/15419069809004468","article-title":"The two poles of the lymphocyte: specialized cell compartments for migration and recruitment","volume":"6","author":"del Pozo","year":"1998","journal-title":"Cell Adhes. Commun."},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0285","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/clin.1994.1091","article-title":"Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules","volume":"71","author":"Rigal","year":"1994","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.01.061_bb0290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-5728(02)00430-7","article-title":"Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies","volume":"135","author":"Creange","year":"2003","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0295","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jns.2017.01.061_bb0300","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1011039216251","article-title":"Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment","volume":"21","author":"Gupta","year":"2001","journal-title":"J. Clin. Immunol."},{"issue":"8","key":"10.1016\/j.jns.2017.01.061_bb0310","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.jns.2017.01.061_bb0315","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3 Pt 1","key":"10.1016\/j.jns.2017.01.061_bb0320","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1212\/WNL.42.3.506","article-title":"Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy","volume":"42","author":"Kaji","year":"1992","journal-title":"Neurology"},{"issue":"8812","key":"10.1016\/j.jns.2017.01.061_bb0325","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0140-6736(92)93267-Q","article-title":"Intravenous immunoglobulin treatment in multifocal motor neuropathy","volume":"340","author":"Charles","year":"1992","journal-title":"Lancet"},{"issue":"8824","key":"10.1016\/j.jns.2017.01.061_bb0330","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/0140-6736(92)93339-O","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"340","author":"Kermode","year":"1992","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0335","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ana.410330303","article-title":"Multifocal motor neuropathy: response to human immune globulin","volume":"33","author":"Chaudhry","year":"1993","journal-title":"Ann. Neurol."},{"issue":"3 Pt 1","key":"10.1016\/j.jns.2017.01.061_bb0340","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1212\/WNL.43.3_Part_1.537","article-title":"High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy","volume":"43","author":"Nobile-Orazio","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2017.01.061_bb0345","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jns5.12046","article-title":"A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy","volume":"18","author":"Hahn","year":"2013","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"11","key":"10.1016\/j.jns.2017.01.061_bb0350","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1212\/01.WNL.0000145706.04340.25","article-title":"Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg","volume":"63","author":"Ruegg","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2017.01.061_bb0355","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","article-title":"Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial","volume":"16","author":"Harbo","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2017.01.061_bb0360","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/archneurol.2011.137","article-title":"Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy","volume":"68","author":"Lin","year":"2011","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.01.061_bb0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1529-8027.2011.00323.x","article-title":"CIDP - the relevance of recent advances in Schwann cell\/axonal neurobiology","volume":"16","author":"Pollard","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"Pt 8","key":"10.1016\/j.jns.2017.01.061_bb0370","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/brain\/awf193","article-title":"Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment","volume":"125","author":"Van den Berg-Vos","year":"2002","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.01.061_bb0375","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jns.2010.02.002","article-title":"Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy","volume":"292","author":"Boerio","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"Pt 11","key":"10.1016\/j.jns.2017.01.061_bb0380","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/brain\/awf255","article-title":"Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease","volume":"125","author":"Priori","year":"2002","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.jns.2017.01.061_bb0385","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","article-title":"How long is IVIg effective in multifocal motor neuropathy?","volume":"62","author":"Terenghi","year":"2004","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2017.01.061_bb0390","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/01.WNL.0000140497.85952.FA","article-title":"Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg","volume":"63","author":"Vucic","year":"2004","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2017.01.061_bb0395","first-page":"1395","article-title":"Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment","volume":"191","author":"Leger","year":"2007","journal-title":"Bull. Acad. Natl Med."},{"issue":"2","key":"10.1016\/j.jns.2017.01.061_bb0400","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2017.01.061_bb0405","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1007\/s10875-014-0016-5","article-title":"Treatment of multifocal motor neuropathy with intravenous immunoglobulin","volume":"34","author":"Koski","year":"2014","journal-title":"J. Clin. Immunol."},{"issue":"7","key":"10.1016\/j.jns.2017.01.061_bb0410","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","article-title":"Side effects of intravenous immunoglobulins in neurological autoimmune disorders\u2014a prospective study","volume":"250","author":"Stangel","year":"2003","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0415","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000073059","article-title":"Therapy with intravenous immunoglobulins: complications and side-effects","volume":"50","author":"Wittstock","year":"2003","journal-title":"Eur. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2017.01.061_bb0420","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00415-009-0969-0","article-title":"Case-control study of thromboembolic events associated with IV immunoglobulin","volume":"256","author":"Caress","year":"2009","journal-title":"J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.01.061_bb0425","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2011.05.035","article-title":"Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study","volume":"308","author":"Rajabally","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"15","key":"10.1016\/j.jns.2017.01.061_bb0430","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"Harbo","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2017.01.061_bb0435","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.jns.2017.01.061_bb0440","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","article-title":"A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study","volume":"16","author":"Misbah","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"11","key":"10.1016\/j.jns.2017.01.061_bb0445","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00415-014-7444-2","article-title":"Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study","volume":"261","author":"Cocito","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2017.01.061_bb0450","doi-asserted-by":"crossref","DOI":"10.1002\/mus.25107","article-title":"Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy","author":"Katzberg","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17300709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17300709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T12:05:02Z","timestamp":1601467502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17300709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":90,"alternative-id":["S0022510X17300709"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.01.061","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulin therapy in the treatment of multifocal motor neuropathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.01.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}